Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2004-06-18
2010-11-23
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S653000, C558S169000
Reexamination Certificate
active
07838562
ABSTRACT:
Agonist of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated forms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels. The sphingosine-1-phosphate receptor agonists can be used for the manufacture of a medicament for treating vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels.
REFERENCES:
patent: 5948820 (1999-09-01), Fujita et al.
patent: 6004565 (1999-12-01), Chiba et al.
patent: 6187821 (2001-02-01), Fujita et al.
patent: 6274629 (2001-08-01), Cottens et al.
patent: 6372800 (2002-04-01), Fujita et al.
patent: 6471980 (2002-10-01), Sirhan et al.
patent: 6476004 (2002-11-01), Sakai et al.
patent: 6486209 (2002-11-01), Cottens et al.
patent: 2001/0056124 (2001-12-01), Cottens et al.
patent: 2003/0082743 (2003-05-01), Bergsma et al.
patent: 2004/0058894 (2004-03-01), Doherty et al.
patent: 03061567 (2003-07-01), None
Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G.J., Card, D., Keohane, C., et al. 2002. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346-349.
Brinkmann, V., Davis, M.D., Heise, C.E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., et al. 2002. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453-21457.
Biedermann, B.C., Sahner, S., Gregor, M., Tsakiris, D.A., Jeanneret, C., Pober, J.S., and Gratwohl, A. 2002. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 359:2078-2083.
Corada, M., Mariotti, M., Thurston, G., Smith, K., Kunkel, R., Brockhaus, M., Lampugnani, M.G., Martin-Padura, I., Stoppacciaro, A., Ruco, L., et al. 1999. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A 96:9815-9820.
Hordijk, P.L., Anthony, E., Mul, F.P., Rientsma, R., Oomen, L.C., and Roos, D. 1999. Vascular-endothelial-cadherin modulates endothelial monolayer permeability. J Cell Sci 112 ( Pt 12):1915-1923.
Garcia, J.G., Liu, F., Verin, A.D., Birukova, A., Dechert, M.A., Gerthoffer, W.T., Bamberg, J.R., and English, D. 2001. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 108:689-701.
Hotchkiss, R.S., Tinsley, K.W., Swanson, P.E., and Karl, I.E. 2002. Endothelial cell apoptosis in sepsis. Crit Care Med 30:S225-228.
Lei, H.Y., Yeh, T.M., Liu, H.S., Lin, Y.S., Chen, S.H., and Liu, C.C. 2001. Immunopathogenesis of dengue virus infection. J Biomed Sci 8:377-388.
Avirutnan, P., Malasit, P., Seliger, B., Bhakdi, S., and Husmann, M. 1998. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol 161:6338-6346.
Garcia, J.G., Siflinger-Birnboim, A., Bizios, R., Del Vecchio, P.J., Fenton, J.W., 2nd, and Malik, A.B. 1986. Thrombin-induced increase in albumin permeability across the endothelium. J Cell Physiol 128:96-104.
Rafi-Janajreh, A.Q., Chen, D., Schmits, R., Mak, T.W., Grayson, R.L., Sponenberg, D.P., Nagarkatti, M., and Nagarkatti, P.S. 1999. Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. J Immunol 163:1619-1627.
McMillan, D.E. 1984. The microcirculation in diabetes. Microcirc Endothelium Lymphatics 1:3-24.
Bates et al.; “Regulation Of Microvascular Permeability by Vascular Endothelial Growth Factors”; J. Anat. 200; pp. 581-597; (2002).
Sanchez, et al. “Phosphorylation and Action of the Immunomodulator FTY720 Inhibits Vascular Endothelial Cell Growth Factor-induced Vascular Permeability” The Journal of Biological Chemistry. vol. 278. No. 47. Nov. 21, 2003. pp. 47281-47290.
Dudek, et al.; “Cytoskeletal Regulation of Pulmonary Vascular Permeability”; J. Appl. Physiol.; 91; pp. 1487-1500; (2001).
Mortelliti, et al.; “Acute Respiratory Distress Syndrome”; American Family Physician; 65; pp. 1823-1830; (2002).
International Search Report and Written Opinion; International Application No. PCT/US2004/019420; International Filing Date: Jun. 18, 2004; Date of Mailing Mar. 10, 2005; 10 pages.
Publication No. EP 1 643 983 ; Application No. 04 776 717.3-2123; Office Action dated Mar. 9, 2007; 2 pages.
Udobi, et al.; “Acute Respiratory Distress Syndrome”; American Family Physician; 67(2); pp. 315-322; (2003).
International Search Report for International Application No. PCT/US2004/019420. International Filing Date of Jun. 18, 2004.
Claffey Kevin Patrick
Hla Timothy
Paik Ji-Hye
Sanchez Teresa
Anderson James D
Cantor & Colburn LLP
Finn Meghan
University of Connecticut
LandOfFree
Methods of inhibiting vascular permeability and apoptosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting vascular permeability and apoptosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting vascular permeability and apoptosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4224877